Insiders Trades
Incyte Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 22 Feb 2022.
Incyte Corp: what insiders have been doing
Headquartered in Wilmington, United States, Incyte Corp belongs to the Healthcare & Pharma sector and traces its origins to 2001. Filings by its managers are published through SEC (Form 4). The last twelve months, up to 18 October 2026, brought 136 filings signed by 25 insiders.
There is no open-market purchase to report; the filings show 32 sales worth €38.1M by 9 insiders. Hoppenot Herve filed the largest sale, €17.1M, on 12 November 2025.
Compared with its exchange (5,813 companies, median 19 filings), a count of 136 filings is above the norm. The full history, which starts in 2016, counts 43 purchases against 69 sales. The 10-K for the year ended 31 December 2025 shows 5.14 bn USD of revenue and 1.29 bn USD of net income.
Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
534
Thresholds
n/a
Buy Volume
€3M
43 ops. · all time
Sell Volume
€50M
69 ops. · all time
Who traded when
BuySalePatrick A. Mayes14 sales
Pablo J. Cagnoni7 sales
Stein Steven H7 sales
Tray Thomas4 sales
Flannelly Barry P2 sales
Iyengar Vijay K2 sales
+5 other insiders
Since the insiders bought
- +14.2%Entry US$67.99 · Close at T+365 US$77.66
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Incyte Corp Buy (bullish), based on 24 analysts. Average price target: US$129.50.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 1,674 of 24,148 companies
76.8
score / 100
Value60
Quality94
FCF yld5.8%
Earn yld5.6%
EV/EBITDA13.1x
ROE31%
Gross mgn93%
Net mgn25%
Debt/EBITDA0.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$113.27
Analyst consensus
24 analystsBuy
US$86.00Target US$129.50(+14%)US$157.00
Income statement
RevenueUS$5.1B
Gross profitUS$4.8B93% margin
EBITDAUS$1.8B34% margin
Net incomeUS$1.3B27.7% margin
Valuation
PER (trailing)14.4x
PER (forward)13.0x
P/Book3.6x
Beta0.74
Balance sheet & cash
Market capUS$23B
Total debtUS$40.4M
Free Cash FlowUS$1.3B
Debt / Equity1%
Profitability & ownership
ROE30.7%
ROA16.8%
% insiders1.8%
% institutions103.5%
Last declaration on 15 October 2026
Declarations534 total
2,642 shares@ US$112.710.0013% mcap3.4% of flowCommonSEC144:0001950047-26-010228
463 shares@ US$117.140.0002% mcap14.0% of flowCommon StockSEC:0002039219-26-000010:0
322 shares0Common StockSEC:0001193125-26-412653:0
203 shares@ US$121.350.0001% mcap0.8% of flowCommon StockSEC:0001409601-26-000015:0
322 shares0Common StockSEC:0001193125-26-412653:1
206 shares@ US$121.350.0001% mcap5.0% of flowCommon StockSEC:0001177917-26-000014:0
920 shares@ US$126.930.0005% mcap100.0% of flowCommon StockSEC:0002085970-26-000007:0
2,957 shares@ US$61.760.0007% mcap0.9% of flowCommon StockSEC:0001205703-26-000030:0
4,551 shares@ US$61.180.0011% mcap1.4% of flowCommon StockSEC:0001205703-26-000030:1
6,477 shares@ US$64.250.0016% mcap2.1% of flowCommon StockSEC:0001205703-26-000030:2
9,233 shares@ US$71.930.0026% mcap3.4% of flowCommon StockSEC:0001205703-26-000030:3
9,233 shares@ US$120.500.0043% mcap5.7% of flowCommon StockSEC:0001205703-26-000030:4
13,985 shares@ US$120.490.0066% mcap8.6% of flowCommon StockSEC:0001205703-26-000030:5
23,218 shares@ US$120.49150.011% mcap32.3% of flowCommonSEC144:0001950047-26-009470
504 shares@ US$129.720.0003% mcap100.0% of flowCommon StockSEC:0002083591-26-000007:0
10,801 shares@ US$125.560.0053% mcap6.9% of flowCommon StockSEC:0001205703-26-000028:0
10,801 shares@ US$125.56150.0053% mcap15.6% of flowCommonSEC144:0001950047-26-008386
10,803 shares@ US$120.040.0051% mcap6.6% of flowCommon StockSEC:0001205703-26-000027:0
10,803 shares@ US$120.03830.0051% mcap15.0% of flowCommonSEC144:0001950047-26-008001
10,640 shares@ US$122.690.0051% mcap6.7% of flowCommon StockSEC:0001205703-26-000025:0
2,207 shares@ US$106.470.0009% mcap2.2% of flowCommon StockSEC:0002079962-26-000015:0
2,207 shares@ US$123.990.0011% mcap2.5% of flowCommon StockSEC:0002079962-26-000015:1
10,640 shares@ US$122.69270.0051% mcap15.1% of flowCommonSEC144:0001950047-26-007678
2,207 shares@ US$123.990.0011% mcap4.6% of flowCommonSEC144:0001950047-26-007673
5,332 shares@ US$119.420.0025% mcap5.9% of flowCommon StockSEC:0002079962-26-000013:16
25 of 534 declarations
About Incyte Corp
Incyte Corp. (NASDAQ: INCY) is a U.S.-based biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for areas of high unmet medical need. Its global headquarters is in Wilmington, Delaware, United States, and the company maintains operations across North America, Europe, and Asia. Incyte was founded in 1991 and went public in 1993. It initially built its reputation in genomics and drug discovery before evolving into a more fully integrated therapeutics company with a core focus on oncology, hematology, and inflammation/autoimmunity. ([investor.incyte.com](https://investor.incyte.com/resources/investor-faqs?utm_source=openai))
From an investor perspective, Incyte is best viewed as a specialty biotech with a combination of marketed products and a substantial clinical pipeline. The company’s commercial portfolio includes Jakafi/Jakavi (ruxolitinib), a well-established therapy in certain myeloproliferative disorders; Opzelura (ruxolitinib cream), which gives Incyte a dermatology franchise; and Zynyz (retifanlimab), its immuno-oncology asset. Incyte also commercializes tafasitamab through Monjuvi in the United States and Minjuvi internationally, strengthening its position in hematology and lymphoma. ([incyte.com](https://incyte.com/?utm_source=openai))
Read moreShow less
Competitively, Incyte stands out by combining a meaningful commercial base with a research engine aimed at differentiated, mechanism-driven medicines. That matters in the highly competitive biotech sector, where execution on late-stage development and regulatory approvals can determine long-term value creation. The company’s strategy is to target diseases where clinical need remains significant and where its scientific expertise can support premium, specialty-market positioning. At the same time, investors should recognize that revenue remains concentrated in a limited number of key franchises, which is common in biotech but still a factor to monitor. ([incyte.com](https://incyte.com/?utm_source=openai))
Geographically, Incyte has a strong U.S. base but a genuinely international footprint, with commercial and development activities extending into Europe and Asia. Recent company highlights include new 2025 clinical data for Opzelura, povorcitinib in hidradenitis suppurativa, INCA033989 in myelofibrosis, and other pipeline assets such as bispecific and KRAS-focused programs. In late 2025 and early 2026, Incyte also reported or advanced multiple regulatory milestones for Zynyz and Minjuvi, underscoring a dense stream of clinical, regulatory, and commercial catalysts. For investors following SEC Form 4 insider activity, the company’s profile on the NYSE/NASDAQ universe is that of a U.S.-listed biotech with recurring commercial revenues and a catalyst-rich development portfolio. ([investor.incyte.com](https://investor.incyte.com/news-releases/news-release-details/incyte-announces-new-data-phase-3b-true-ad4-trial-opzelurar?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
